Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Therapeutic potential of mesenchymal stem cells on cholesterol homeostasis-associated genes in AD-like rats.

Karimi Darabi M., Rafeeinia A., Pezeshki SP., Nazeri Z., Kheirollah A., Cheraghzadeh M.

Animal Study on Neuroinflammation, published in FASEB J (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
FASEB J (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
39751793
DOI
10.1096/fj.202401167RR

Abstract (original English)

Cholesterol is vital for nerve processes. Changes in cholesterol homeostasis lead to neurodegeneration and Alzheimer's disease (AD). In recent years, extensive research has confirmed the influential role of adipose tissue mesenchymal stem cells (MSCs) in managing AD. The present study aims is to investigate a new approach concerning AD by MSCs with particular reference to the cholesterol homeostasis pathway and its regulatory miRNAs in an AD-like rat model. Three groups of 24 male Wistar rats have been divided: healthy rats (control), Alzheimer's rats (AD), and Alzheimer's rats that received MSCs (AD + MSC). Cholesterol level was measured using the GC-mass technique. The mRNA and expression levels of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), apolipoprotein E (APOE), ATP-binding cassette transporter A1 (ABCA1), and CYP46A1 genes, as well as their regulating miRNAs, were assessed using real-time polymerase chain reaction (RT-PCR) and western blotting techniques, respectively. Intraventricular transplantation of MSCs improved behavioral disorders and decreased the count of Aβ plaques in brain tissue. Transplantation of these cells also led to a significant decrease in cholesterol levels and HMGCR, ApoE, and ABCA1 and a remarkable increase in CYP46A1 mRNAs and protein expression. These cells considerably changed the expression of microRNAs regulating these genes. These resu

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMaleCholesterolRatsRats, WistarAlzheimer DiseaseATP Binding Cassette Transporter 1Mesenchymal Stem CellsHomeostasisMesenchymal Stem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research